2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

2/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系

基本信息

批准号：
10249136
负责人：
ERNEST MARTINEZ
金额：
$ 27.29万
依托单位：
UNIVERSITY OF CALIFORNIA RIVERSIDE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-02 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10249136
关键词：
Acetylation Address Affect African American American Antelopes Antineoplastic Agents Award Bioinformatics California Cell Line Cities City of Hope Comprehensive Cancer Center Clinical Collaborations Color Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Development Drug Design Drug Targeting Drug resistance Education Engineering Ensure European Faculty Fellowship Fostering Funding Goals Grant Hispanic Americans Hispanics Individual Inequality Infrastructure Institution Investments Joints Latina Latino Los Angeles Malignant Neoplasms Master&apos s Degree Mentors Mentorship Minority Mitochondrial Proteins Not Hispanic or Latino Participant Patients Pharmaceutical Preparations Phase Physicians Population Postdoctoral Fellow Precision Medicine Initiative Prognosis Reporting Research Personnel Resources Scientist Societies Students System Testing Therapeutic Therapeutic Agents Tissues Toxic effect Training Training Programs United States United States Food and Drug Administration United States National Institutes of Health Universities Woman Work anticancer research cancer health disparity clinical translation clinical trial participant disparity elimination disparity reduction diversity and equity diversity and inclusion drug development drug discovery ethnic diversity malignant breast neoplasm manufacturing facility medical schools men minority communities news next generation novel therapeutics phase 1 testing precision medicine programs screening success therapeutic development training opportunity triple-negative invasive breast carcinoma

项目摘要

ABSTRACT Cancer drugs in the United States are almost exclusively developed by, tested in, and optimized for European- Americans. Disparities in U.S. drug development are the result of long-standing inequalities that occur throughout the entire drug discovery pipeline. Only a small number of basic, translational and clinical scientists are Latino/Hispanic or Black/African-American. Less than 2-5% of trial participants are Latino/Hispanic or Black/African-American. Yet, in spite of a lack of data, new drugs are approved by the U.S. Food and Drug Administration (FDA) and subsequently prescribed for Latino/Hispanic or Black/African-American patients, without sufficient testing. It is unacceptable, especially in this era of the Precision Medicine Initiative (PMI), that currently our drugs are developed by, and optimized for, only for an exclusive segment of our citizens. We seek to shift this paradigm by strengthening the existing partnership between University of California at Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoH-CCC). In this proposed P20, UCR and CoH-CCC will partner to develop the resources, infrastructure, and training programs necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. We anticipate that our P20 program will drive new collaborative R01 grants and K01 and T-type training grants. .

抽象的美国的癌症药物几乎由针对欧洲进行，测试和优化。美国人。美国药物开发的差异是长期存在的不平等现象的结果在整个药物发现管道中。只有少数基本，转化和临床科学家是拉丁裔/西班牙裔或黑人/非裔美国人。不到2-5％的审判参与者是拉丁裔/西班牙裔或黑人/非裔美国人。然而，尽管缺乏数据，但新药得到了美国食品和药物的批准行政（FDA），随后针对拉丁裔/西班牙裔或黑人/非裔美国人的患者规定没有足够的测试。这是不可接受的，尤其是在这个精密医学倡议（PMI）时代，目前，我们的药物是由我们的公民专有部分开发的，并为其优化。我们寻求通过加强加利福尼亚大学AT之间的现有合作伙伴关系来改变这一范式 Riverside（UCR）和希望之城综合癌症中心（COH-CCC）。在此提议的P20中 COH-CCC将合作开发必要的资源，基础设施和培训计划发展下一代的治疗研究人员，反映了内陆南部的种族多样性加利福尼亚。我们预计我们的P20计划将推动新的协作R01赠款以及K01和T-Type 培训补助金。。